Dynamic changes of neutralizing antibody and memory T cell responses six months post Omicron XBB reinfection
With the continued prevalence of COVID-19, repeated infection caused by SARS-CoV-2 has become common. However, studies on immune persistence post Omicron XBB reinfection are limited. We prospectively studied the durability and cross-reactivity of neutralizing antibodies (NAbs) and T cell responses a...
Saved in:
Published in | Frontiers in immunology Vol. 15; p. 1477721 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
07.10.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | With the continued prevalence of COVID-19, repeated infection caused by SARS-CoV-2 has become common. However, studies on immune persistence post Omicron XBB reinfection are limited.
We prospectively studied the durability and cross-reactivity of neutralizing antibodies (NAbs) and T cell responses among 20 subjects who suffered Omicron BA.5 infection with or without Omicron XBB reinfection over 6-month through the pseudovirus neutralization test and the fluorospot assay.
NAbs against EG.5.1, BA.2.86, and JN.1 subvariants were decreased and undetectable at 6-month post Omicron BA.5 infection, while those elicited by Omicron XBB reinfection were significant increased and remained detectable against all detected variants within 6-month. Furthermore, in subjects with Omicron XBB reinfection, memory T cell responses could cross-recognized wild-type and Omicron spike peptides and reached peak at 3-month. Interestingly, comparable robust T cell responses were observed among non-seroconverted subjects post Omicron XBB exposure.
Though the NAbs against various emerging Omicron subvariants elicited by Omicron XBB reinfection can persist for at least 6-month, the HCWs should strengthen personal protection and timely be immunized with updated vaccines upon current circulating variants or conserved T epitope. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors have contributed equally to this work and share last authorship Cyril Planchais, Institut Pasteur, France Reviewed by: Huang Huang, Gilead, United States Edited by: Tara Marlene Strutt, University of Central Florida, United States The authors have contributed equally to this work and share first authorship |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2024.1477721 |